A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR-322 when used in combination with insulin in subjects with type 2 diabetes.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of SYR-322 when used in combination with insulin in subjects with type 2 diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Alogliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2009 Results were published in Diabetes, Obesity and Metabolism.
    • 09 Sep 2008 Results presented at the 44th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top